Caswell, J. Why Cholesterol Matters. http://heartinsight.heart.org/Summer-2017/Why-Cholesterol-Matters/ Heart Insight Magazine.
 World Health Organization. Global Status Report on Noncommunicable Diseases 2014. Geneva, 2014.
 National Heart, Lung, and Blood Institute. How To Prevent and Control Coronary Heart Disease Risk Factors. Accessed April 10, 2018.
 Kuklina, EV. Centers for Disease Control and Prevention. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol. United States, 1999–2002 and 2005–2008. MMWR. 2011;60(4):109–14.
 Zhao S, Wang Y, Mu Y, Yu B, Ye P, Yan X, Li Z, Wei Y, Ambegaonakr BM, Hu D, Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS), Atherosclerosis (2014), doi: 10.1016/ j.atherosclerosis.2014.05.916.
 Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. DOI:
 国家心血管病中心. 中国心血管病报告 2017. 北京: 中国大百科全书出版社
 Repatha Prescribing Information; Amgen, Thousand Oaks, CA, 2017.